Literature DB >> 8975946

Early development of experimental biliary pancreatitis and its amelioration by CCK-receptor blockade.

C Niederau1, F Borchard, R Lüthen, M Niederau.   

Abstract

BACKGROUND/AIMS: Development of pancreatitis has extensively been studied in models using CDE-diet and cerulein. This study analyzes early alterations and effects of CCK-receptor blockade in a model of biliary pancreatitis which better reflects the pathogenesis of human pancreatitis.
MATERIAL AND METHODS: The common part of the bile and pancreatic duct was surgically ligated in fed rats which were allowed to recover. The CCK-antagonist CR1409 at 10 mg/kg or 0.9% NaCl was s.c. given every 6 hours. Morphological alterations were quantified by histological grading. Biochemical evidence of pancreatitis was assessed by determination of amylase concentrations in serum and ascites. A bioassay was used to determine plasma cholecystokinin.
RESULTS: Ligation of the common bile and pancreatic duct caused an increase in serum amylase, development of ascites with high amylase concentrations, and morphological evidence of pancreatitis without major mortality. Electron microscopy showed early loss of microvilli and defects in basal lamina representing initial stages of duct ruptures. Early ultrastructural damage to acini included multiple vacuoles, peripheral loss of density of ("targetoid") zymogen granules and dilatation of RER. Acinar vacuolization, edema, hemorrhage and necrosis mainly occurred in areas neighboring the ducts. Duct ligation was associated with a significant increase in plasma CCK. The CCK-antagonist significantly reduced the biochemical and morphological severity of obstructive pancreatitis.
CONCLUSIONS: Obstruction of the common channel of the bile and pancreatic ducts results in transient mild to moderate acute pancreatitis and in an increase in plasma CCK. Since CCK-receptor blockade ameliorated the severity of pancreatitis it is likely that increased plasma CCK plays a contributory or permissive role in pancreatitis caused by duct obstruction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8975946

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Cholecystokinin antagonists may have detrimental effects on acute pancreatitis.

Authors:  Isabel De Dios; Manuel A Manso
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

2.  Low enzyme content in the pancreas does not reduce the severity of acute pancreatitis induced by bile-pancreatic duct obstruction.

Authors:  Ana De La Mano; Sara Sevillano; Isabel De Dios; Secundino Vicente; Manuel Antonio Manso
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

3.  Effect of carbon dioxide pneumoperitoneum on the severity of acute pancreatitis: an experimental study in rats.

Authors:  S Yol; E B Bostanci; Y Ozogul; N I Zengin; U Ozel; A Bilgihan; M Akoglu
Journal:  Surg Endosc       Date:  2004-10-26       Impact factor: 4.584

4.  Acute taurodeoxycholate-induced pancreatitis in the rat is associated with hyperCCKemia.

Authors:  B Ohlsson; J Axelson; U Stenram; J F Rehfeld; I Ihse
Journal:  Int J Pancreatol       Date:  2000-06

5.  Cholecystokinin in acute alcoholic and biliary pancreatitis.

Authors:  S Räty; J Sand; E Kemppainen; S Laine; I Nordback
Journal:  Int J Pancreatol       Date:  2000-08

Review 6.  Do cholecystokinin antagonists increase cytosolic calcium in pancreatic acinar cells and thereby promote pancreatitis?

Authors:  Claus Niederau
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 7.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

8.  Cholecystokinin antagonist L364,718 induces alterations in acinar cells that prevent improvement of acute pancreatitis induced by obstruction.

Authors:  Isabel De Dios; Aranzazu Uruñuela; Alberto Orfao; Manuel A Manso
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.